Abstract:Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease worldwide and is increasingly being diagnosed at younger ages, affecting more than one-third of young people with obesity. Objective: To evaluate associations between perinatal conditions and risk of MASLD and associated progressive liver disease. Design, setting, and participants: This nationwide, population-based case-control study included all biopsy-confirmed cases of MASLD in Sweden. Individuals aged 25 years or younger (hereafter, young individuals) with biopsy-proven MASLD between January 1, 1992, and December 31, 2016, were matched to up to 5 general population control individuals. Granular data on maternal and perinatal characteristics were retrieved from the Swedish Medical Birth Register. Data were analyzed from June 2023 to June 2024. Exposures: Birth weight (low [<2500 g], reference [2500 to <4000 g], or high [≥4000 g]), gestational age (GA), and birth weight for GA (small for GA [SGA; <10th percentile], appropriate for GA [10th-90th percentile], or large for GA [LGA; >90th percentile]), compared between patients and matched controls. Main outcomes and measures: The main outcome was odds of biopsy-proven MASLD and MASLD-associated progressive liver disease (ie, liver fibrosis or cirrhosis) according to birth weight, GA, and birth weight for GA, adjusted for matching factors. Results: In total, 165 young individuals with biopsy-proven MASLD (median age at diagnosis: 12.0 years [IQR, 4.4-16.9 years]; 100 [60.6%] male) were matched with 717 controls. There was an association between low birth weight and future development of MASLD (adjusted odds ratio [AOR], 4.05; 95% CI, 1.85-8.88) but no association between high birth weight and odds of MASLD (AOR, 0.64; 95% CI, 0.38-1.08) compared with the reference birth weight. An association was seen for SGA (AOR, 3.36; 95% CI, 2.00-5.64) compared with appropriate size for GA (reference category) but not for LGA (AOR, 0.57; 95% CI, 0.27-1.20). Progressive liver disease was more common in individuals born with low birth weight (AOR, 6.03; 95% CI, 1.66-21.87) or SGA (AOR, 4.90; 95% CI, 2.15-11.14). Conclusions and relevance: In this nationwide study of young individuals with biopsy-proven MASLD, low birth weight and SGA were associated with development of MASLD and progressive liver disease, suggesting a need for structured screening measures to diagnose these conditions early in high-risk individuals.

MENTAL FUNCTION AND GROWTH IN CHILDREN WITH EARLY (E) VS. LATE (L) ONSET END-STAGE LIVER DISEASE (ESLD)

VITAMIN E DEFICIENCY IN EARLY ONSET LIVER DISEASE AFFECTS MENTAL DEVELOPEMNT

Assessment of School Readiness in Chronic Cholestatic Liver Disease: A Pilot Study Examining Children with and without Liver Transplantation

Nonfasted Liver Stiffness Correlates with Liver Disease Parameters and Portal Hypertension in Pediatric Cholestatic Liver Disease

Distinct Longitudinal Trajectories of Symptom Burden Predict Clinical Outcomes in End-Stage Liver Disease

Liver Transplantation in Children with Urea Cycle Disorders: The Importance of Minimizing Waiting Time

Psychometric Hepatic Encephalopathy Tests and Electroencephalogram Results Among Cirrhotic Patients

Preservation of fat mass at the expense of lean mass in children with end‐stage chronic liver disease

S1883 Evaluating Differences in Screening Between Pediatric and Adult Patients for Development of Metabolic Dysfunction-Associated Steatotic Liver Disease at an Academic Primary Care Clinic

MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Birth Weight, Gestational Age, and Risk of Pediatric-Onset MASLD

Growth Hormone Treatment Normalized Liver Enzymes in an Adolescent with Obesity and Short Statute

Characterization of 42 Egyptian Children with Lysosomal Storage Disorders

Developmental delay can precede neurologic regression in early onset metachromatic leukodystrophy

Natural History of Liver Disease in a Large International Cohort of Children with Alagille Syndrome: Results from the GALA Study

Concern about Liver Disease in Children

Cognitive Development in Infantile-Onset Pompe Disease under Very Early Enzyme Replacement Therapy.

The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years

Early diagnosis and treatment by newborn screening (NBS) or family history is associated with improved visual outcomes for long-chain 3-hydroxyacylCoA dehydrogenase deficiency (LCHADD) chorioretinopathy

Long‐Term Amino Acid Homeostasis, Neurodevelopmental and Growth Profiles Following Liver Transplantation in Maple Syrup Urine Disease

Longitudinal evaluation of pediatric and young adult metabolic dysfunction-associated steatotic liver disease defined by MR elastography